Unlock Insights Into Stroke Research With Our Canine Ischemic Stroke Model Case Study

Ace Therapeutics' Canine Ischemic Stroke Model offers a powerful translational solution—combining human-like neurovascular anatomy and longitudinal multimodal imaging with neurological scoring to generate clinically meaningful preclinical data.

This detailed case study showcases how Ace Therapeutics successfully established and validated a stable, reproducible canine ischemic stroke model, supporting both transient ischemia–reperfusion and permanent MCA occlusion paradigms.

By downloading the case study, you will gain insight into:

A Highly Translational Large-Animal Stroke Model

• Brain anatomy and vascular structures closely resembling those of humans
• Compatibility with minimally invasive, imaging-guided arterial interventions
• Reduced translational risk compared with small-animal models, without the logistical and ethical complexity of NHP studies

Longitudinal, Multimodal Imaging Strategy

• Integrated CT, MRI (T2-weighted imaging), and optional TOF-MRA
• Serial image registration and fusion for precise infarct tracking
• Dynamic assessment of vascular recanalization, infarct evolution, and cerebral edema over a 28-day period

Functional Outcomes that Matter

• Modified neurological severity scoring (mNSS)
• Blinded, quantitative evaluations aligned with imaging readouts

From Acute Injury to Recovery: A Complete Stroke Trajectory

The case study highlights how the canine model captures the full temporal evolution of ischemic stroke:

• Acute phase (3–24 hours): Rapid edema formation and infarct expansion
• Subacute phase (3–7 days): Peak tissue damage and neurological deficits
• Recovery phase (10–28 days): Edema resolution, lesion stabilization, and functional improvement

Download the Case Study

Discover how Ace Therapeutics' Canine Ischemic Stroke Model can elevate your preclinical stroke program with clinically relevant anatomy, imaging, and functional outcomes.

You might be interested in...